Inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cell lines

Ying Qian1,2
Yanning Liu3
Qiuyue Yan1,2
Juan Lv2
Xiaoyan Ni2
Yunlu Wu1,2
Xuejun Dong1,2

1The Key Laboratory of Laboratory Medicine, Ministry of Education of China; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 2Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang, People’s Republic of China; 3State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang, People’s Republic of China

Keywords: Mus81, siRNA, 5-FU, breast carcinoma, chemosensitivity, p53

Introduction

Breast cancer is one of the most common malignant tumors among women all over the world.1,2 Combination chemotherapy is a conventional choice for breast cancer after surgery in the clinic. Currently, 5-fluorouracil (5-FU) plus cyclophosphamide and doxorubicin or epirubicin is widely used to treat breast carcinoma. However, some studies have found that breast cancers show different degrees of primary or acquired resistance to 5-FU,3,4 and high doses of drugs will result in several adverse side effects to healthy cells. Therefore, improving the chemotherapy sensitivity is important for optimized treatment.

The methyl methanesulfonate and ultraviolet sensitive 81 independent gene (MMS and UV sensitive number 81, Mus81) is widely conserved among eukaryotes.5–8 Mus81 protein is a kind of endonuclease that can remove damaged or aberrant DNA fragments to ensure normal DNA replication.9 Mus81-deficient embryonic stem cells and mice...
were found to be hypersensitive to mitomycin C (MMC): the survival rate of Mus81−/− and Mus81+/- genotypes of embryonic stem cells and mice were significantly lower than the wild type in response to the same dose of MMC.8 Disruption of Mus81 gene would increase the sensitivity to MMC and cisplatin, and this sensitivity could be downregulated to normal after expressing Mus81 again.9 In addition, the clonogenic survival of Mus81−/− fibroblast cells was decreased by Cr [VI] (hexavalent chromium) exposure in a dose-dependent manner compared to wild-type controls.10 Other studies reported that the expressions of Mus81 in different tumor cells correlated well with their sensitivity to cisplatin; also, Mus81 expression was increased in 5-FU-resistant pancreatic cancer cells.11 Therefore, a targeting agent that is specific to Mus81 is potentially a promising method for chemosensitivity improvement, especially in Mus81-positive breast carcinoma.

The present study aimed to examine the effect of Mus81 on the chemosensitivity to 5-FU of MCF-7 and T47D cells.

**Materials and methods**

**Cell cultures**

The human breast carcinoma cell lines MCF-7 and T47D cells were obtained from the Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, People’s Republic of China). MCF-7 cells were cultured in minimum essential medium ([MEM] Hyclone, MA, USA). T47D cells were cultured in Dulbecco’s Modified Eagle’s Medium ([DMEM] Hyclone). Both MEM and DMEM were supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA.), penicillin (100 U/mL), and streptomycin (100 mg/mL). Cells were cultured at 37°C in a 5% CO₂ atmosphere.

**siRNA transfection**

When the cells had grown to 30%–80% confluency, the medium was changed to serum-free and antibiotics-free medium. Mus81 expression was knocked down by transfection with siRNA (Generpharma, Shanghai, People’s Republic of China) directed against protein of interest at the final concentration of 100 nM. An siRNA duplex that shared no homologous sequences with the target gene was used as a negative control. Transfection was performed using Lipofectamine® 2000 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. The efficiency of transfection was determined by quantitative real-time (RT) polymerase chain reaction (PCR) and Western blot analysis. The first Mus81 siRNA (siMus81) sequence was 5'-CUGCU-GAGCACAUAAAGU-TT-3' and 5'-ACUUAUGGGUG-CUCAGCAGTTT-3'. The second siMus81 sequence is 5'-ACGCGCUUCAUUUAUCCA GATT-3' and 5'-UCU-GAAAUCGAAGCGC GUTT-3'. The third siMus81 sequence is 5'-GCAGGAGCCAU CAAGAUA UATT-3' and 5'-UAUUCUUGAUGG CUCUCGCTT-5'. The control siRNA sequence is 5'-UUCUCGACUGUCGAGU TT-3' and 5'-ACGUGACACGUUCGGAGAATT-3'.

**Quantitative RT-PCR**

Cells were seeded in a six-well plate at a density of 5×10⁴ cells/well in medium containing 10% fetal bovine serum at 37°C, 5% CO₂. After transfection with Mus81 siRNAs (siMus81-1, siMus81-2, siMus81-3), control siRNA (siCtrl) for 24 hours, total RNA was extracted. RNA was isolated from the cells using TRizol® (Thermo Fisher Scientific) and reverse transcribed using the first-strand cDNA synthesis kit (Biomiga, San Diego, USA) according to the manufacturer’s protocol. Quantitative RT-PCR was performed with the Lightcycler® 480 PCR apparatus (Hoffman-La Roche Ltd, Basel, Switzerland). PCR primers were used as follows: Mus81, forward nucleotide, 5’-TGTGGA CATTGGCCAGAC-3’, reverse nucleotide, 5’-GCTGAGGTTGTGGACGGA-3’; and β-actin, forward nucleotide, 5’-ACCCACACTGTGCCCATCTAC-3’, reverse nucleotide, 5’-TCGGTGAGAATCT TCATGAGGT-3’. The abundance of the Mus81 transcript was expressed relative to the control of β-actin. The experiments were performed independently three times.

**Western blot**

Cells were harvested and rinsed with phosphate buffered saline. Cells were lysed for total protein extraction using RIPA lysis buffer (Beyotime, Jiangsu, People’s Republic of China). The protein concentration was determined by the Bicinchoninic Acid assay (Beyotime, Nantong, People’s Republic of China). Equal amounts of proteins were separated using 10% gel electrophoresis. Then, the proteins were transferred to PVDF membranes (Whatman, Maidstone, Kent, UK), which were blocked in 5% bovine serum albumin. PVDF membranes were incubated with primary antibodies against Mus81 (1:1,000; Abcam, Cambridge, UK), p53 (1:1,000; Abcam), and β-actin (1:5,000; Abcam) overnight at 4°C. After incubations with horseradish peroxidase-conjugated secondary antibodies (1:10,000; Abcam) for 1 hour at room temperature, the blots were developed using the chemiluminescence detection kit ECL-Plus (Thermo Fisher Scientific, New York, USA) according to the manufacturer’s instructions.
Then, blots were exposed to a radiographic film. β-Actin expression was used as a control.

**Cell viability assays**

Cells were seeded (5x10^4/well) in 96-well plates and then transfected with siMus81 for 24 hours. MCF-7 cells were further treated with 5-FU (Bioer Technology, Hangzhou, People's Republic of China) at concentrations ranging from 0.625 µg/mL up to 10 µg/mL for 48 hours. T47D cells were further incubated with 5-FU at concentrations ranging from 2.5 µg/mL up to 40 µg/mL for 48 hours. Finally, 10 µL tetrazolium salt WST-8 (Cell Counting Kit-8 [CCK-8]; Keygen, Nanjing, People's Republic of China) was added to each well (final volume ratio as 10%). Optical density was measured at a wavelength of 450 nm (OD450). Cell viability was calculated as follows:

\[
\text{Viability of cells} = \frac{\text{Drug-given group OD450}}{\text{Control group OD450}} \times 100\%. \quad (1)
\]

**Plate colony formation assay**

Cells were transfected with siMus81 for 24 hours and were seeded onto six well-plates at a density of 1000 cells per well. Then, MCF-7 cells were treated with 2.5 µg/mL 5-FU and T47D cells were treated with 25 µg/mL 5-FU for 4 hours and allowed to grow for 7 days until visible clones appeared. Cell colony formation was assessed using Giemsa solution. The colony containing more than 50 cells was counted and the number of colonies was calculated. The colony formation rate was calculated using the following equation:

\[
\text{Colony formation rate} = \frac{\text{Number of colonies}}{\text{Number of seeded cells}} \times 100\%. \quad (2)
\]

**Apoptosis assay**

Cells were transfected with siMus81 for 24 hours, seeded onto six-well plates at a density of 4x10^4 cells per well. 5-FU (2.5 µg/mL) was added to MCF-7 cells and 25 µg/mL 5-FU were added and the cells left for 48 hours. Cells from each group were harvested and diluted with phosphate buffered saline twice. Then, 5 µL of fluorescein isothiocyanate and 5 µL of propidium iodide (PI) (Annexin V-FITC Kit; Keygen) were added to 500 µL of cells. After incubation in the dark for 5–15 minutes at room temperature, flow cytometry was carried out. The experiments were performed independently three times.

**Cell cycle**

After transfection and drug treatment, cells were harvested and fixed in 70% alcohol overnight at 4°C, incubated with 100 µL trypsin for 30 minutes at 37°C, and incubated with 400 µL PI for 30 minutes in the dark. In the end, cells were analyzed by flow cytometry.

**Statistical analysis**

All data were expressed as mean ± standard deviation, and SPSS 17.0 software was used for statistical analyses. One-way analysis of variance (ANOVA) and Student’s t-test were used to analyze the significance between groups. P<0.05 was considered statistically significant.

**Results**

siMus81 suppresses mRNA and protein expression of Mus81

MCF-7 and T47D cells were transfected with siMus81. The FAM fluorescence could be detected in successfully transfected cells (Figure 1A). The transfection efficiency of MCF-7 and T47D cells, which was further confirmed by flow cytometric assay, was 82.47% and 78.18%, respectively (Figure 1A). Twenty-four hours after transfection, the inhibition efficiency of siMus81 was measured by quantitative RT-PCR. Compared with the siCtrl group, Mus81 mRNA expression levels of MCF-7 cells in three siMus81 groups were markedly reduced, to 39.15±1.93%, 30.79±2.01%, and 21.48±2.74%, respectively. Western blot analysis also showed that Mus81 protein expression levels of MCF-7 were significantly decreased after transfection with siMus81 for 24, 48, and 72 hours (Figure 1B and C). These results showed that siMus81 could effectively reduce the mRNA and protein levels of Mus81 in MCF-7 cells, and the third sequence of siMus81 was the most effective one. As a result, we chose siMus81-3 for subsequent experiments. Mus81 mRNA expression levels of T47D cells in siMus81 group were reduced to 33.61±2.85%, compared with the siCtrl group. The amount of Mus81 protein also significantly decreased 24, 48, and 72 hours after transfection with siMus81-3 (Figure 1D). The Mus81 mRNA and protein expression levels of both MCF-7 and T47D cells showed significant reduction after siMus81 transfection.

**Inhibition of Mus81 sensitizes breast cancer cells to 5-FU**

**Cell viability assay**

The cell viability of breast cancer cells was examined by CCK-8 analysis. The OD450 values of MCF-7 cells in the siCtrl and siMus81 groups were 1.39±0.30 and 1.31±0.26, respectively; the difference between the two groups was
not statistically significant \((P>0.05)\). Also, the OD450 values of T47D cells in the siCtrl and siMus81 groups were 1.12±0.34 and 1.16±0.31, respectively; this difference was also not statistically significant \((P>0.05)\). 5-FU could decrease the cell viabilities of MCF-7 and T47D cells in a dose-dependent manner (Figure 2). At the same time, we examined the sensitivity of MCF-7 and T47D cells in the siMus81 and siCtrl groups to 5-FU. The cell viability in the siMus81 groups was decreased compared to the siCtrl groups in response to 5-FU in both MCF-7 and T47D cells (Figure 2).

Colony formation assay
We next examined the ability of Mus81-suppressed cells to form colonies by exposure to 5-FU. The clone formation rate of MCF-7 cells in the siMus81 group was significantly lower than in the siCtrl group \((39.97\%±9.30\% \text{ versus } 63.23\%±9.21\%, \ P<0.05)\) after 5-FU treatment (Figure 3A and B). The clone formation rates of T47D cells in the siMus81 group and siCtrl group were 37.26%±7.32% and 66.33%±10.26%, respectively. siMus81 significantly inhibited colony formation of T47D cells compared with the siCtrl group \((P<0.05)\) (Figure 3C and D).

These data show that Mus81 inhibition resulted in an increased sensitivity of both MCF7 and T47D cells to 5-FU.

Inhibition of Mus81 affects cell cycle of breast cancer cells with 5-FU
siMus81 and siCtrl did not affect the cell cycle of MCF-7 and T47D cells without 5-FU. The G2 proportions of MCF-7 cells with 5-FU in the siCtrl group and in the siMus81 group were 23.63±1.52% and 41.81±1.30%, respectively. G2 proportions increased significantly in the siMus81 group compared with the siCtrl group after 5-FU treatment \((P<0.05)\) (Figure 4A and B). Inhibition of Mus81 also affected cell cycle of T47D cells, and siMus81 combined with 5-FU caused G2 phase accumulation \((P<0.05; 30.44\%±1.55\%\text{ for siMus81 group and }18.31\%±2.10\%\text{ for siCtrl group})\) (Figure 4C and D).

Inhibition of Mus81 increases apoptosis of MCF-7 cells with 5-FU
To explore whether chemosensitivity induced by siMus81 is due to the increase of cell apoptosis, we detected the apoptotic rate in MCF-7 and T47D cells after exposure to 5-FU. Forty-eight hours after drug treatment, flow cytometry (FC) analysis for annexin V/PI revealed a marked increase of apoptotic MCF-7 cells in the siMus81 group compared to the siCtrl group \((41.92\%±4.82\% \text{ versus } 27.27\%±3.98\%, \ P<0.05)\) (Figure 5A and B). However, there was no difference in the apoptotic rates of T47D cells.
between the siMus81 group and the siCtrl group with 5-FU treatment (43.57%±6.34% versus 39.87%±9.17%, P>0.05) (Figure 5C and D).

siMus81-transfected MCF-7 cells express elevated levels of p53 in response to 5-FU. p53 induces cell apoptosis and plays an important role in the response to DNA-damaging agents. Because Mus81 inhibition combined with 5-FU caused increased apoptosis, we examined the p53 expression of MCF-7 in response to 5-FU-induced DNA damage. Similarly to the siCtrl group, the siMus81 group did not show elevated basal levels of p53 expression. However, Western blot analysis indicated that the p53 expression level of MCF-7 cells increased more in the siMus81 group than in the siCtrl group with 5-FU (Figure 6).

**Figure 2** Cell viability assay.

Notes: (A) The cell viability of MCF-7 cells was determined by CCK-8 assay after exposure to 5-FU. Twenty-four hours after siRNA transfection, cells were exposed to 5-FU for 48 hours, and then cell viability was determined by CCK-8 assay. The results were normalized against blank, siCtrl and siMus81 group without 5-FU treatment, respectively (mean ± SD, n=3). (B) The cell viability of T47D cells was determined by CCK-8 assay after exposure to 5-FU. Twenty-four hours after siRNA transfection, cells were exposed to 5-FU for 48 hours, and then cell viability was determined by CCK-8 assay. The results were normalized against blank, siCtrl and siMus81 group without 5-FU treatment, respectively (mean ± SD, n=3).

Abbreviations: 5-FU, 5-fluorouracil; CCK-8, Cell Counting Kit-8; siCtrl, control siRNA; siMus81, Mus81 siRNA; SD, standard deviation; siRNA, small interfering RNA.

**Figure 3** Colony formation assay.

Notes: (A and C) colony forming assay of MCF-7 and T47D cells. (B and D) clone formation rate of each group. Colonies were counted on day 7, and analysis was performed (mean ± SD, n=3).

Abbreviations: 5-FU, 5-fluorouracil; siCtrl, control siRNA; siMus81, Mus81 siRNA; SD, standard deviation; siRNA, small interfering RNA.
Abbreviations: cells with small interfering RNA.

Discussion

In this study, we found that the Mus81-silenced breast cancer MCF-7 and T47D cells exhibited decreased cell viability, clonogenic survival, and G2 accumulation in response to 5-FU. Inhibition of Mus81 only increased apoptosis of MCF-7 cells, not T47D cells treated with 5-FU. We investigated for the first time a mechanism through which the suppression of Mus81 might contribute to p53-mediated chemosensitivity improvement.

Mus81 is a DNA repair gene found in recent years. Mus81 has been shown to participate in a repair pathway by generation of double-strand break intermediates. Mus81-Eme1/Mms4 complex, by processing stalled replication forks, free 3′-flap structures, Holliday junctions, and so on, is vital for DNA damage repair and maintenance of chromosomal stability. Chromosome instability and DNA damage are the main characteristics of cancer cells. Mammalian cells

Figure 4 Inhibition of Mus81 affects cell cycle of breast cancer cells with 5-FU.

Notes: Twenty-four hours after transfection, cells were exposed to 5-FU for 48 hours. Cell cycle of MCF-7 cells was analyzed by flow cytometric assay (A), and data are presented as mean ± SD of three independent experiments (B). Cell cycle of T47D cells was analyzed by flow cytometric assay (C), and data are presented as mean ± SD of three independent experiments (D). Proportion of G2 phase was increased significantly in the siMus81 group compared with the siCtrl group in both MCF-7 and T47D cells with 5-FU treatment.

Abbreviations: 5-FU, 5-fluorouracil; siCtrl, control siRNA; siMus81, Mus81 siRNA; SD, standard deviation; siRNA, small interfering RNA.

Figure 5 Inhibition of Mus81 affects apoptosis of MCF-7 cells with 5-FU.

Notes: (A) Apoptosis of MCF-7 cells analysis was with combination FITC and annexin V and PI assay. (B) The apoptosis of MCF-7 cells increased in the siMus81 group in response to 5-FU (mean ± SD, n=3). (C) Apoptosis of T47D cells was analyzed by FITC-annexin V/PI assay. (D) The apoptosis of T47D cells did not increase in the siMus81 group in response to 5-FU (mean ± SD, n=3).

Abbreviations: 5-FU, 5-fluorouracil; FITC, fluorescein isothiocyanate; PI, propidium iodide; siCtrl, control siRNA; siMus81, Mus81 siRNA; SD, standard deviation; siRNA, small interfering RNA.
deficient in Mus81 or Eme1 have previously been shown to be selectively hypersensitive to DNA-damaging agents that result in stalled replication forks. It has also been reported that Mus81 was a marker of cisplatin resistance in different kinds of tumor cells.

In this study, we inhibited Mus81 expression by siMus81 and examined the changes of chemotherapy sensitivity of MCF-7 and T47D cells to 5-FU. The results of quantitative RT-PCR and Western blot demonstrated that the mRNA and protein expression of Mus81 could be significantly suppressed by all three of the siMus81s, especially siMus81-3. Thus, we chose siMus81-3 for the proceeding studies. Cell viability assay and colony formation assay are two classic experiments for examining the sensitivity of cancer cells to drugs. Cell viability is a common effect of proliferation and apoptosis. Cell viability is a common effect of proliferation and apoptosis. Clone formation rate reflects the cell group dependence and single cell proliferation ability by DNA-damaging stress. By using CCK-8 and plate colony formation assay, we found that both the cell viability and clonogenic survival of MCF-7 and T47D cells with 5-FU were significantly decreased after Mus81 inhibition. The above data reveal that Mus81 inhibition can improve the sensitivity of breast carcinoma cells to 5-FU via reducing cell proliferation.

Cell cycle arrest has been demonstrated to be involved in the growth inhibition by DNA-damaging drugs. Our study revealed that Mus81 suppression by siRNA could affect the cell cycle distribution of MCF-7 and T47D cells by 5-FU treatment and that the proportion of G2 period was significantly increased in the siMus81 group compared to in the siCtrl group. Moreover, another study has shown that Mus81 silenced by gene targeting could activate the intra-S-phase and G2/M checkpoints of cancer cells, thereby inducing an increase in sensitivity to MMC, MMS, cisplatin, ultraviolet radiation, ionizing radiation, and hydroxyurea. Pamidi et al also found that treatment with MMC resulted in an accumulation in the G2 phase of Mus81-deficient cells. These results are consistent with our study. Thus, cell cycle arrest might contribute to enhanced sensitivity by Mus81 deficiency.

Annexin V analysis proved that the loss of Mus81 increased the apoptosis of MCF-7 cells treated with 5-FU. Mus81 inhibition can improve the sensitivity of MCF-7 cells to 5-FU via increasing cell apoptosis; however, Mus81 inhibition did not affect the apoptosis of T47D cells treated with 5-FU. We hypothesize that influence of Mus81 on apoptosis is different in different cells. The mechanism for this remains unclear.

p53 is one of the important cell cycle regulatory proteins and is able to induce cell apoptosis. DNA damage signal through ATM/ATR or via CHK1/CHK2 can activate p53 in a direct or indirect manner, respectively. p53 can upregulate the cell cycle inhibitory proteins and induce cell apoptosis. Mus81–/– mouse embryonic fibroblasts display an elevated level of p53 in response to MMC. Furthermore, mutant cells sensitive to Mus81–/– cells returned to wild-type level after inhibiting the activity of p53. In our study, we found that the p53 expression level of MCF-7 cells in the siMus81 group increased more remarkably than that in the siCtrl group after 5-FU exposure. We speculated that Mus81 inhibition enhanced apoptosis of MCF-7 cells to 5-FU via upregulation of p53.

Conclusion
This study shows that Mus81 silenced by siRNA can suppress the cell viability and colony formation of MCF-7 and T47D cells. Hence, inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cells, mainly via reducing cell proliferation. We will further study the mechanism of Mus81 participating in chemosensitivity in the future. We will verify effectiveness of siMus81 in an animal model.

Acknowledgments
This study was supported by the Natural Science Foundation of Zhejiang Province (Y14H200002), Medicines Health Platform Key Project of Zhejiang Province (2013ZDA024), and Key Science and Technology Innovation Team of Zhejiang Province (2012R100-48-09).

Disclosure
The authors report no conflicts of interest in this work.
References

1. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. *Cancer Epidemiol*. 2012;36(3):237–248.

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer*. 2010;127(12):2893–2917.

3. Porrka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. *J Clin Oncol*. 1994;12(8):1639–1647.

4. He Z, Yuan J, Chen Z, Liu S, Shen Z, Fei H. [Chemosensitivity test for 170 human breast carcinoma samples]. *Huanan Yi Ke Da Xue Xue Bao*. 1998;23(6):531–534. Chinese.

5. Interthal H, Heyer WD. *MUS81* encodes a novel helix-hairpin-helix protein involved in the response to UV- and methylation-induced DNA damage in Saccharomyces cerevisiae. *Mol Gen Genet*. 2000;263(5):812–827.

6. Boddy MN, Lopez-Girona A, Shanahan P, Interthal H, Heyer WD, Russell P. Damage tolerance protein Mus81 associates with the FHA1 domain of checkpoint kinase Cds1. *Mol Cell Biol*. 2000;20(23):8758–8766.

7. Chen XB, Melchionna R, Denis CM, et al. Human Mus81-associated endonuclease cleaves Holliday junctions in vitro. *Mol Cell*. 2001;8(5):1117–1127.

8. Hartung F, Suer S, Bergmann T, Puchta H. The role of AtMUS81 in DNA repair and its genetic interaction with the helicase AtRecQ4A. *Nucleic Acids Res*. 2006;34(16):4438–4448.

9. Hanada K, Budzowska M, Davies SL, et al. The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. *Nat Struct Mol Biol*. 2007;14(11):1096–1104.

10. McPherson JP, Lemmers B, Chahwan R, et al. Involvement of mammalian Mus81 in genome integrity and tumor suppression. *Science*. 2004;304(5678):1822–1826.

11. Dedouga N, Gao H, Moechars D, Janicot M, Viallard J, McGowan CH. Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. *Mol Cell Biol*. 2005;25(17):7569–7579.

12. Tamblyn L, Li E, Srikanta H, Srikanta P, Hande MP, McPherson JP. A role for Mus81 in the repair of chromium-induced DNA damage. *Mutat Res*. 2009;660(1–2):57–65.

13. Tomoda Y, Katsura M, Okajima M, Hosoya N, Kohno N, Miyagawa K. Functional evidence for Eme1 as a marker of cisplatin resistance. *Int J Cancer*. 2009;124(12):2979–3000.

14. Feng XJ, Fu Z, Bai JF, Shi Y, Sun YM, Zhao HL. Identification of genes associated with 5-fluorouracil resistance in human pancreatic cancer cells. *Acta Universitatis Medicinae Nanjing (Natural Science)*. 2010;30(6):756–762.

15. Boddy MN, Gaillard PH, McDonald WH, Shanahan P, Yates JR 3rd, Russell P. Mus81-Eme1 is essential for the regulation of the DNA replication fork. *DNA Repair (Amst)*. 2007;6(7):1004–1017.

16. Osman F, Whitby MC. Exploring the roles of Mus81-Eme1/Mms4 at perturbed replication forks. *DNA Repair (Amst)*. 2007;6(7):1004–1017.

17. Murfuni I, Nicolai S, Baldari S, et al. The WRN and MUS81 proteins limit cell death and genome instability following oncogene activation. *Oncogene*. 2013;32(5):610–620.

18. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving hallmark of cancer. *Nat Rev Mol Cell Biol*. 2010;11(3):220–228.

19. Hiyama T, Katsura M, Yoshimura T, et al. Haploinsufficiency of the Mus81-Eme1 endonuclease activates the intra-S-phase and G2/M checkpoints and promotes rereplication in human cells. *Nucleic Acids Res*. 2006;34(3):880–892.

20. Hanada K, Budzowska M, Modesti M, et al. The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. *EMBO J*. 2006;25(20):4921–4932.

21. Shimura T, Torres MJ, Martin MM, et al. Bloom’s syndrome helicase and Mus81 are required to initiate transient double-strand DNA breaks in response to DNA replication stress. *J Mol Biol*. 2008;375(4):1152–1164.

22. Pamidi A, Cardoso R, Hakem A, et al. Functional interplay of p53 and Mus81 in DNA damage responses and cancer. *Cancer Res*. 2007;67(18):8527–8535.

23. Ou YH, Chung PH, Sun TP, Shieh SY. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. *Mol Biol Cell*. 2005;16(4):1684–1695.

24. Meek DW. The p53 response to DNA damage. *DNA Repair (Amst)*. 2004;3(8–9):1049–1056.